Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Input Output* HealthCare 2.0 billion R&D staff: ~7,500 CropScience 0.8 billion R&D staff: ~4,400 MaterialScience 0.2 billion R&D staff: ~900 26% R&D budget 2012: 3.0 billion 8% 65% Around 40 projects in clinical development or approval procedure, including five products with peak sales potential of 5 billion in total Our integrated product pipeline in crop protection and seed technology contains over 30 projects with estimated launch dates 2011-2016, plus numerous seed varieties Other 27 million R&D staff: ~100 1% New products and applications across all business units; leading-edge process technology for world-scale plants. * As of February 2013 Page 2 1
Bayer HealthCare Pharmaceuticals Excellent progress with pipeline Xarelto TM Reduces thrombosis risk Cardiology Oncology Adempas TM Stivarga TM Xofigo TM Reduces pressure in lung arteria Inhibits multiple enzymes that cause tumor growth Acts specifically against bone metastases Innovative products: cardiovascular, cancer & eye diseases Ophthalmology EYLEA TM Inhibits formation of new blood vessels at the back of the eye Page 3 Increasing challenges in the Healthcare Market Aging Population Patients / Consumers gain more Influence Highly efficient healthcare industry Rising costs and pressure on healthcare industry manufacturers Increasing Value Requirements Find options to de-risk research and increase flexibility Understand needs and specifics of diseases prevalent in emerging markets Need to come up with breakthrough innovation From Emerging Markets to Growth Markets Improve molecular understanding of disease mechanisms, better models, patient stratification These challenges cannot be addressed by the healthcare industry alone: partnerships are a key component Page 4 2
Our partners value true collaborations with close interaction and exchange of expertise. What was valued and is important to our partners Impact on organizing the partnership Partners seek for Partner Collaborations on eye-level with close interaction, exchange of expertise and mutual benefit Clear strategy and long-term perspective generate added value for all involved parties complementary expertise Excellent collaboration partners Sharing of knowledge Feedback from our partners: Bayer Bayer has high scientific expertise and good partnership management Excellent internal Drug Discovery expertise Long-term, reliable partnership Good partner interaction High level of mutual trust which allows for in-depth sharing of knowledge. ¹ Page 5 ¹ Insights based on a survey conducted with 52 partners from Biotech (23), CROs (3), and Academia (26) in May/June 2012. An integrated partnering approach to generate added value for all parties is key to success. Innovative and tailored Partnering Models 1 Internal Organization and processes: We focus on excellence in alliance and partnership management Added Value 2 Tailored and innovative partnering models: We focus on-eye-level` partnerships Internal Organizational Structures and Processes People s skills, partnering culture and mindset 3 Appropriate Skill set and open culture: We foster an open culture and skills by trainings and open innovation concepts Partnering is part of our Global Drug Discovery organization as an integrated function: Global External Innovation & Alliances Page 6 3
Partnerships are an integrative part of Global Drug Discovery Global External Innovation & Alliances is part of BHC Global Drug Discovery Global External Innovation & Alliances focuses on: Development & management of strategic alliances & open innovation initiatives Research Policy and public funding Strategic Outsourcing VC Investments Local Hubs: Innovation Center China Science Hub US Science Hub Singapore San Francisco Boston Headquarter Berlin Beijing Singapore Global External Innovation & Alliances is responsible for research partnering activities of Bayer HealthCare Global Drug Discovery Page 7 ¹ Global Drug Discovery Bayer HealthCare s approach of flexible partnering models Within BHC Type Involvement Examples Joint labs Close interaction, shared labs DKFZ Strategic innovation partnership Consortia Multiple projects, close interaction Broad Institute, Evotec Innovative Med.Initiative Joint research Crowdsourcing Outsourcing Individual project Singapore Network G4T, G4L Wuxi Apptech Licensing Transition of assets LDC Dortmund Incubator Arm s length CoLaborator SF/Berlin Venture Investments High Tech Gründerfonds Strategic Alliances and Open Innovation approaches are key elements for Breakthrough Innovation Page 8 4
Novel partnership models: Strategic alliance Bayer Healthcare and the German Cancer Research Center Strategic Alliance and Joint Lab of Bayer, DKFZ and NCT Heidelberg German Cancer Research Center (DKFZ) is one of the largest biomedical oncology research centers in Europe First agreement signed in 2009, collaboration extended for another 5 years in 2014 Collaboration along the entire drug discovery and development value chain Novel risk and reward sharing approach to collaborate with joint financing (up to 30 mio EUR within the next 5 y) and project selection (currently 26 joint projects) Extension of partnership by joint laboratory for immunotherapies at the National Center for Tumor Diseases (NCT) in Heidelberg in 2013 Bench Bedside Page 9 BHC Open Innovation Family Grants4Targets Grants4Leads Grants4Apps CoLaborator BHC grants for targets/ biomarkers. Offers expertise, tools and technologies to help develop your ideas. BHC grants to assess small molecule leads which may lead to collaborations to explore such leads. BHC grants for innovative IT projects which may lead to new business models. Unique incubator for startup life-science companies aligning with Bayer s interests. San Francisco Berlin http://www.grants4targets. com http://www.grants4leads. com http://www.grants4 apps.com http://colaborator.bayer. com Page 10 5
Novel type of partnering: Crowd Sourcing Challenge* to be solved defined by seeking institution (pharma company) Internet as communication platform Review Collaboration (industry and academia) to address challenges Solutions/ideas provided by scientific community * such as the search for novel targets, compounds or indications for known assets Source: Lessl et al., 2011, Nature Drug Discovery 10, 241-242 Page 11 Crowd sourcing: www.grants4targets.com Page 12 6
Novel Type of partnering our Grants4Targets Initiative Background Numerous targets exist, but are invisible for us The knowledge outside > inside Idea Join forces with academia and biotech start ups to translate innovative targets into drugs Provision of grants to evaluate and validate novel targets Grants 4 Targets Approach Easily accessible Internet site and submission tool Low bureaucratic burden for both partners Clear communication on needs what are we looking for? Fast processing of requests Target Discovery Lead Generation Lead Optimization Preclinical Clinical Submission http://www.grants4targets.com Page 13 Grant types within G4T program Support Grants ( 5,000-10,000) to further advance research on targets that are at a very early stage of discovery; fixed grant approval letter; IP rights remain with the applicant Focus Grants ( 10,000-125,000) for more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug-discovery process; fixed grant approval letter; IP rights remain with the applicant 7
Visitors [-] Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug G4T is running for 5 years and has completed 10 rounds of applications 1027 applications received 133 grants approved (12% acceptance rate) Most of the ideas are novel to us 2% 24% 9% 7% 22% 38% Germany Europe w/o D USA Asia RoW 55% 11% 11% 7% 14% marketed ongoing BSP project under evaluation in-house terminated project no current project not applicable Lessl et al., Drug Discovery Today 2011, Vol 16, 288-292 10 rounds of applications completed World-wide footprint Now attracting almost 3000 visitors / month 4000 Visitors per Month 3000 2000 1000 0 2009 2010 2011 2012 2013 Month 15 Bayer is planning to open the CoLaborator in Berlin in May 2014 Key features 800 m 2 assigned lab and office space on Bayer HealthCare s campus in the heart of Berlin for up to 9 start-up companies A new home for startups in life sciences with ideas related to Bayer HealthCare s R&D strategy Proximity to Bayer HealthCare research and the vicinity to Berlin s science and startup community create an eco-system for innovative ideas. Page 16 8
VC investments to promote innovative start-ups in HealthCare Page 17 We apply the RESOLVE¹ model for professional Alliance Management incorporated in our research organization. Value of Relationship and Culture Focus on personal relationships: trust, respect Behave as real partners Create awareness and manage diversity Value communication Open communication and exchange of information, active conflict resolution Mutual feedback on performance Mutual Benefit and Added Value Enthusiasm / commitment Commitment at all levels Willingness to overcome resistance Share credit Strategic fit Identify match partners with complementary strengths / skills Complementary and transparent goals Learning capabilities Openness to learn from each other Value from cross-organizational learning Drivers / motivation of partners to be steered in common direction Professional operational management Well-defined processes Transparent governance Goal orientation, clear objectives Clear Agreements on IP publications and payments ¹ Lessl & Douglas: Wissenschaftsmanagement. (2) 2010, p 34-41 Page 18 9
Collaborative Innovation is a key concept of our strategy Bayer HealthCare is committed to Innovation Science for a better Life Strategic Partnering on eye-level is an integral part of our Drug Discovery Strategy We strive for tailored partnering concepts generating added value for both parties An integrated partnering approach ensures pipeline impact and value generation for our patients Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 10